2017 Judges


Ian Schwartz

Sartorius Stedium

Ian Schwartz recently joined Sartorius Stedim Biotech as a Process Development Consultant. Ian has over 12 years of experience in the biotechnology industry and specializes in developing and implementing scalable platforms for process development and manufacture of biologics to speed development and reduce risks to successful manufacture. Prior to joining Sartorius Stedim Biotech, Ian gained experience in process development and manufacturing operations through positions of increasing responsibility at ImmunoGen, MedImmune, and Agensys.  

John Lambert


Dr. Lambert earned a Ph.D. in Biochemistry (1976) from University of Cambridge (England, UK), under the supervision of Professor Richard N. Perham.  After postdoctoral training at the University of California, Davis (1976-1980), and University of Glasgow, Scotland (1980-1982), Dr Lambert joined the Dana-Farber Cancer Institute, Harvard Medical School working on the ImmunoGen-funded programs to develop antibody-drug conjugates (ADCs) and immunotoxins as anti-cancer therapeutics. The company established independent laboratories in Cambridge, Massachusetts in 1987. Dr. Lambert served as Chief Scientific Officer from 2008 until 2015, at which time he was appointed Distinguished Research Fellow. He served on the executive committee as Executive Vice President , Research, from 2008 until 2017, at which time he was appointed EVP Emeritus.  He is the author/co-author of over 120 peer-reviewed scientific publications. In 2016, Dr Lambert was elected a Fellow of the American Institute for Medical and Biological Engineering (AIMBE).

Jagath Reddy Junutula

Cellerent Therapeutics

Jagath Reddy Junutula, PhD joined Cellerant in April 2014 as a Vice President, Research & Development. Prior to joining Cellerant, Jagath was at Genentech for 13 years focusing on oncology drug discovery and development, including discovery and validation of targets for treatment of cancer; design, development and pre-clinical validation of antibody drug conjugates (ADCs); engineering next-generation ADCs; and development of bi-specific antibody/protein based cancer immunotherapeutic platforms for treatment of different types of cancers.  He developed a novel THIOMAB technology platform to generate site-specific antibody-drug conjugates (ADCs) to improve the therapeutic utility of antibodies. This technology has widely been accepted as a new standard for the development of therapeutic ADCs.  He led the teams, which discovered and developed a next generation site-specific T-DM1 ADC project and over 10 other ADC/Bi-specific antibody therapeutic candidates. He obtained his PhD in 1997 from the Indian Institute of Science, Bangalore, India, and did post-doctoral research in Germany as an Alexander von Humboldt fellow and at Stanford University.  Jagath has authored 90 peer-reviewed publications/patents and has presented his work at numerous international conferences. Jagath serves as an editorial board member of leading journals, mAbs & ACS Medicinal Chemistry Letters. He served as a President (2010-2011) and Board Chairman (2013-2014) of EPPIC Global, a non-profit organization that fosters entrepreneurial mentoring, partnering and networking among Pharma/Biotech professionals.

Hans-Peter Gerber

Maverick Therapeutics

Hans-Peter has more than 20 years of research and development experience in the field of biotherapeutics research and development in oncology, including antibody-drug conjugates (ADC), redirected T-cell targeting compounds and nanoparticles. Most recently he was CSO of Pfizer’s Bioconjugates division where he was leading Pfizer’ s efforts in both, ADC and bispecific, redirected T-cell targeting platform- and program development. He previously held senior leadership positions at Seattle Genetics and Genentech. Hans-Peter is currently CSO and President at the immune-oncology company Maverick Therapeutics, Inc. Dr. Gerber is a member of the board at NBE Therapeutics, an early stage ADC company located in Basel, Switzerland, developing ADC with a unique and novel mechanism of action.   Hans-Peter is an internationally recognized leader in Oncology drug discovery and development, with a strong record of accomplishments in the field of antibody-based, targeted therapeutics. His work has led to more than six IND filings for ADCs and bi-specifics, and contributions to BLA submissions of therapeutic antibodies and two ADCs in Oncology. He is an author on over 90 peer-reviewed published papers and inventor on 15 patents in the field of Oncology drug discovery. Hans-Peter Gerber received an MS in Biochemistry and a PhD in Molecular Biology from the University of Zurich, Switzerland.